News
Home » News

Accelerating our understanding of neuroendocrine tumors to find better treatments
Growing small intestinal organoids in a petri dish. Sequencing the “runaway” DNA of a pancreatic neuroendocrine tumor from a blood sample. Evaluating whether environmental or infectious agents contribute to the development of NETs. The research programs funded by NETRF this year push the search for the causes of this disease to the horizon of emerging scientific research.

NETRF Makes $4 Million in Grants to Advance Research of a Poorly Understood Cancer
(April 25, 2017, Boston, MA)—The Neuroendocrine Tumor Research Foundation (NETRF) today announced its largest research commitment ever—$4 million in collaborative grants—most from its new Accelerator

NETRF recognized as top-tier charity
NETRF’s strong financial position, transparency, and accountability again earned it a 4-star rating by Charity Navigator, a national evaluator of nonprofits. The 4-star rating indicates
Exploring the Use of Immunotherapy in NETs
NETRF is pleased to announce awards for world-class research to explore the potential of immunotherapy in NETs. This rapidly expanding class of therapies has proven

Petersen Investigator: Michael German, MD
Michael German, MD has been named a Petersen Investigator for his work to explore the use of an FDA approved inhibitor of Mek1/2 in preclinical

The Neuroendocrine Tumor Research Foundation partners with Pattern.org to enable patients to directly contribute tissue samples to research projects.
The Neuroendocrine Tumor Research Foundation is excited to be working with Pattern.org to empower patients to direct their excess cancer tissue samples to research projects.

NETRF Collaborates with ERF to Fund Nuclear Medicine NET Grant
The first NETRF/ERF Nuclear Medicine Pilot Research Grant has been awarded to Thomas Hope, MD, of the University of California at San Francisco (UCSF). NETRF
Josh Mailman Joins NETRF Board of Directors
The NETRF Board of Directors is pleased to announce that Josh Mailman has joined the Board. Josh is an internationally-recognized advocate for Neuroendocrine tumor patients

Petersen Investigator Dr. Gigi Lozano: Working to unlock the mysteries of Pancreatic Neuroendocrine Tumors
Dr. Guillermina Lozano, Ph.D. of MD Anderson Cancer Center has worked tirelessly to understand how pancreatic neuroendocrine tumors develop so that we might use that

NETRF/NANETS Names First BTSI Researcher
Dr. Christopher Heaphy of Johns Hopkins University has been selected as the first Basic Translational Science Investigator, through a collaboration between NETRF and The North